The convergence of artificial intelligence (AI) and omics technologies—genomics, transcriptomics, proteomics, and metabolomics—transforms healthcare and biomedical research by enabling unprecedented insights into disease mechanisms, personalized medicine, and predictive diagnostics. AI enhances the analysis of large-scale, complex omics datasets, driving advancements in precision medicine, disease diagnosis, biomarker discovery, drug development, and public health. In radiology and pathology, AI-powered algorithms improve diagnostic accuracy and efficiency, reducing human error and accelerating clinical workflows. Omics data provides a systems-level understanding of biological processes, aiding in identifying genetic mutations, disease pathways, and therapeutic targets. Despite these advancements, significant challenges remain, including data quality, standardization, ethical concerns, computational complexity, and algorithmic biases. Addressing these challenges is critical to ensure AI-driven solutions’ reliability, fairness, and scalability in clinical settings. Innovations such as explainable AI models, federated learning approaches, and multi-omics integration frameworks hold promise for overcoming current limitations. These advancements will facilitate the seamless integration of AI and omics into healthcare, enabling novel biomarker discovery, refined disease subtyping, and tailored treatment strategies. The synergy between AI and omics is poised to revolutionize precision medicine, accelerate drug discovery, enhance public health surveillance, and promote equitable healthcare delivery. This transformative integration will pave the way for a more informed, inclusive, and resilient healthcare ecosystem by fostering interdisciplinary collaboration and addressing existing barriers.